Alzheimer’s patients retain the benefits of Leqembi even when they stop the drug, Eisai says
[ad_1] Research at Biogen Source: Biogen Alzheimer’s patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai shows. The Japanese drugmaker and its partner Biogen last week released an additional analysis of clinical trials of the monoclonal antibody drug, which is also known as lecanemab. Alzheimer’s disease continued to progress at a slower…